Zobrazeno 1 - 10
of 82
pro vyhledávání: '"O, Stoss"'
Publikováno v:
Der Pathologe. 41:606-613
Fur die HER2-gerichtete Therapie ist der Nachweis einer Rezeptor-Uberexpression und/oder der Genamplifikation mittels In-situ-Hybridisierung (ISH) von entscheidender Bedeutung. Im Laufe von mehr als 15 Jahren haben die Amerikanische Krebsgesellschaft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7d070c2c2e27acfb8d531b466dd9cba
https://doi.org/10.1007/s00292-020-00841-5
https://doi.org/10.1007/s00292-020-00841-5
Publikováno v:
Der Pathologe. 42(Suppl 1)
A prerequisite for all HER2 directed therapies is the demonstration of HER2 receptor protein overexpression and/or gene amplification by in situ hybridization (ISH). ASCO and CAP have published several HER2 test guidelines over the past 15 years for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb8d776ef22891b69151835773a6bac0
https://pubmed.ncbi.nlm.nih.gov/33346874
https://pubmed.ncbi.nlm.nih.gov/33346874
Autor:
Markus Tiemann, Hans-Ulrich Schildhaus, Manfred Dietel, Iver Petersen, Felix Lasitschka, Ulrich Sommer, Peter Schirmacher, Rolf Diezko, Josef Rüschoff, Thomas Henkel, Simone Reu, Thomas Kirchner, Kristina Schwamborn, Jürgen Wolf, Wilko Weichert, Arne Warth, Reinhard Büttner, Gustavo Baretton, O. Stoss, Korinna Jöhrens, Gudrun Baenfer, Lukas C. Heukamp, Bharat Jasani, Andreas H. Scheel
Publikováno v:
Histopathology. 72:449-459
Aims PD-L1 immunohistochemistry has become a mandatory diagnostic test in the treatment of lung cancer. Several research-initiatives have started to harmonize the five PD-L1 immunohistochemistry assays that have been used in clinical trials. Here we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a933ebe98b9c47909bf5190626ec6a6
https://doi.org/10.1111/his.13375
https://doi.org/10.1111/his.13375
e14265 Background: In the context of immuno-oncology related cancer treatment, tumor mutational burden (TMB) is currently explored as a predictive biomarker for several human malignancies. Several sequencing assays are increasingly commercially avail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28928b2a026e4db58a0d8352c970af37
Autor:
O. Stoss, Thomas Henkel, Michael Untch, Iris Nagelmeier, Andreas H. Scheel, Bharat Jasani, Josef Rüschoff, Giuseppe Viale, H. U. Schildhaus
Publikováno v:
Modern Pathology. 28:1528-1534
Recently the American Society of Clinical Oncology and the College of American Pathologists have updated their clinical practice guidelines for HER2 testing in breast cancer. In order to evaluate these new recommendations, we have re-assessed the HER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a7c56cbf924e327f54e493f0e71bf41
https://doi.org/10.1038/modpathol.2015.112
https://doi.org/10.1038/modpathol.2015.112
Autor:
O. Stoss, J. E. Boers, B. P. L. Wijnhoven, J. J. B. van Lanschot, Winand N.M. Dinjens, P. M. van Hagen, Katharina Biermann, Hein F.B.M. Sleddens, J. Rueschoff
Publikováno v:
Diseases of the Esophagus. 28:380-385
Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of esophageal adenocarcinomas. Frequently, biopsy material is used for evaluation of HER2 status. The aim of the study was to determine if HER2 expression in preoperative en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cd1a2481adbadd17de70fb7981e3981
https://doi.org/10.1111/dote.12204
https://doi.org/10.1111/dote.12204
Autor:
O. Stoss, Urania Dafni, M Arfi, Lila Zabaglo, Martine Piccart-Gebhart, Marion Procter, Janine Salter, Josef Rüschoff, Ian Bradbury, Mitch Dowsett, D Zielinski
Publikováno v:
Annals of Oncology. 24:2761-2766
Trastuzumab treatment improves survival of HER2-positive primary breast cancer. HER2 staining intensity varies widely in HER2-positive tumours. We investigated whether differences in immunohistochemical (IHC) staining intensity for HER2 in HER2-posit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f48af8e6e42bd2d56a854ad965ff1fbf
https://doi.org/10.1093/annonc/mdt275
https://doi.org/10.1093/annonc/mdt275
Autor:
Manfred Dietel, O. Stoss, H.H. Kreipe, Reinhard Büttner, Josef Rüschoff, Iris Nagelmeier, W. Schlake, H. U. Schildhaus, Gustavo B. Baretton, Heinz Höfler
Publikováno v:
Der Pathologe. 31:208-217
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0f1d9e74ce5822e6628d3b0e2e8c006
https://doi.org/10.1007/s00292-010-1278-1
https://doi.org/10.1007/s00292-010-1278-1
Publikováno v:
Geburtshilfe und Frauenheilkunde. 69:711-716
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac64c6f829288df7b2a5ad01965c160f
https://doi.org/10.1055/s-0029-1185923
https://doi.org/10.1055/s-0029-1185923
Publikováno v:
Der Pathologe. 30:147-155
Die Bestimmung des ErbB2/Her-2/neu-Status ist heute essenzieller Bestandteil der Mammakarzinomdiagnostik und Voraussetzung fur eine Anti-ErbB2-Therapie. Untersuchungsmethoden am Tumorgewebe sind der Nachweis der Rezeptoruberexpression mittels Immunhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6b92ffbc3ac3a9f6c1a13aeb2b3c72e
https://doi.org/10.1007/s00292-009-1126-3
https://doi.org/10.1007/s00292-009-1126-3